TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque-Reference-Cited by-同舟云学术

TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque

Published:2013-10 Issue: Volume:73 Page:337-347
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Johnston Tom H.,Huot Philippe,Fox Susan H.,Koprich James B.,Szeliga Kendall T.,James John W.,Graef John D.,Letchworth Sharon R.,Jordan Kristen G.,Hill Michael P.,Brotchie Jonathan M.

Funder

The Michael J. Fox Foundation for Parkinson's Research

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference43 articles.

1. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys;Blanchet;Mov. Disord.,1998

2. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease;Bordia;J. Pharmacol. Exp. Ther.,2008

3. Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization;Bordia;J. Pharmacol. Exp. Ther.,2010

4. l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective;Buck;Drug Discov. Today,2010

5. Impact of the motor complications of Parkinson's disease on the quality of life;Chapuis;Mov. Disord.,2005

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia;Neuropharmacology;2024-05

2. Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction;Journal of Medicinal Chemistry;2023-08-31

3. Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases;Cells;2023-08-11

4. Role of P11 through serotonergic and glutamatergic pathways in LID;Molecular Biology Reports;2023-02-28

5. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic;Neurodegenerative Disease Management;2022-08